Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
293.11(c) 296.85(c) 298.38(c) 296.03(c) 295.59 Last
570 330 742 567 781 239 571 450 271 611 Volume
-0.14% +1.28% +0.52% -0.79% -0.15% Change
More quotes
Financials (USD)
Sales 2019 7 650 M
EBIT 2019 2 360 M
Net income 2019 2 010 M
Finance 2019 4 498 M
Yield 2019 -
Sales 2020 8 164 M
EBIT 2020 2 870 M
Net income 2020 2 429 M
Finance 2020 7 091 M
Yield 2020 -
P/E ratio 2019 16,9x
P/E ratio 2020 14,3x
EV / Sales2019 3,65x
EV / Sales2020 3,10x
Capitalization 32 392 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.2%); - supply of collaborative services (32.6%): working with Sanofi... 
Sector
Biotechnology & Medical Research
Calendar
09/09 | 08:10amPresentation
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
08/15REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
08/14REGENERON PHARMACEUTICALS : FDA Approves EYLEA Injection Prefilled Syringe
AQ
08/14REGENERON PHARMACEUTICALS : Announces Positive Topline Results from Phase 3 Tria..
PR
08/13REGENERON PHARMACEUTICALS : FDA Approves EYLEA® (aflibercept) Injection Prefille..
PR
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/12REGENERON PHARMACEUTICALS : PALM Ebola Clinical Trial Stopped Early as Regeneron..
PR
08/07REGENERON PHARMACEUTICALS : Dupixent Showed Positive Topline Results in Phase 3 ..
AQ
08/07REGENERON PHARMACEUTICALS : Dupixent Approved by European Commission for Adolesc..
AQ
08/07SANOFI : - Dupixent approved by European Commission for adolescents with moderat..
AQ
08/06MARKET SNAPSHOT: Dow Bounces Back From Worst Day Of 2019 As S&P 500 Ends 6-da..
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
08/07Hedge fund Hoplite Capital plans to shut down - letter
RE
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 384,33  $
Last Close Price 296,03  $
Spread / Highest target 67,6%
Spread / Average Target 29,8%
Spread / Lowest Target 5,73%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-20.74%32 392
GILEAD SCIENCES1.42%80 344
VERTEX PHARMACEUTICALS10.87%47 223
GENMAB28.01%13 210
NEUROCRINE BIOSCIENCES, INC.35.88%8 886
BEIGENE LTD--.--%8 765